Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.

ABSTRACT:

Purpose

Identification of single-nucleotide polymorphisms (SNP) associated with development of advanced colorectal adenomas.

Experimental design

Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence. Genome-wide significance was defined as false discovery rate less than 0.05, unadjusted P = 7.4 × 10(-7). Validation phase: results were further evaluated using 4,175 familial colorectal adenoma cases and 5,036 controls from patients of European ancestry [COloRectal Gene Identification consortium (CORGI), Scotland, Australia, and VQ58].

Results

Our study id

SUBMITTER: Wang J 

PROVIDER: S-EPMC4037290 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature